Prenetics Global Limited (PRE) Earnings Call Transcript
May 14, 2026
Earnings Call Speaker Segments
Okay, thanks so much. Morning, everybody. I'm calling in from New York today. Really appreciate you all being here with us. In addition to the earnings release that came out this morning, I'd ask everyone to take a look at our newest investor presentation, which you can find on our site, prenetics.com. There's plenty of fresh cohort information in there that's worth your time. Let me just begin by noting that 17 months back, we rolled out IM8 with one product, zero customers, and no revenue at all. As of now, we ship to 43 countries, we're delivering about 150,000 servings daily, and we're on pace to hit somewhere around $186 million in annualized recurring revenue, using IM8's May monthly revenue as the base. That's what product market fit at scale looks like. Q1 stood out as our strongest quarter yet as a consumer health company. April and May are shaping up even better. This morning I'd like to lay out three things: the company we've turned into, the engine behind these figures, and what comes next. So, first, the company. When Prenetics went public in 2022, it was a diagnostics and genome testing operation centered on lab testing. A revenue model that looked very different, a different growth trajectory. What you're looking at today is a completely different Prenetics; we're now a care play consumer health company with IM8 at its core. Subscription revenue that recurs, gross margins that keep widening, distribution around the world in 43 countries, operating disciplines centered on unit economics. During the last 9 months, we've also shed three businesses — ACT Genomics, Europa, and Insighta — moving that capital into the growth asset we believe in most. The brand, the team, the science, and the channels have all been rebuilt. So when you look at our results, look at them with that in mind. In every way that matters, this is a new company. Turning to Q1, on a continuing operational basis, total revenue came in at $36 million, roughly 333% higher year-over-year. IM8 added $33.8 million, almost 6x year-over-year, and 23% above the prior quarter, which was already a strong Q4. IM8 gross margins widened to 64%, an improvement of about 400 basis points from quarter to quarter. Gross profit rose 315% year-over-year, reaching $23.3 million. Active subscribers climbed to 82,000. Subscriptions accounted for 93% of IM8 revenue. Servings delivered rose 28% sequentially, hitting 8.8 million for the quarter. That reflects actual consumption, not orders simply parked in pantries. This acceleration hasn't slowed down. April brought $14 million in IM8 monthly revenue, an 18.6% gain over March. For May, IM8 monthly revenue is tracking toward about $15.5 million, which implies annualized recurring revenue of approximately $186 million. The most significant thing we accomplished this quarter wasn't a product launch — it was finishing the global rollout of quarterly subscriptions. We began with the U.S. in Q4 of last year and took it worldwide in Q1. The effect has been enormous. Our average order value has climbed from about $110 for full year 2025 to a new customer average order value of $157 in Q4 2025 and then $240 in Q1 2026. That's a 53% sequential rise and more than double our full year 2025 baseline. The amount of time it takes for us to get our money back is shrinking, our cash generation is getting better, and most importantly, keeping customers has appeared to be more solid. Roughly 79% of our new customers sign up for a subscription, which is basically the same as what we saw in Q4. Nobody is being coerced into making a lengthy commitment. They are opting for it since the offering delivers results. I'd like to walk you through the cohort figures, as that's where things become truly compelling. In January 2026, our quarterly cohort brought in $587 of cumulative revenue per customer in only 4 months; to put that in perspective, our January 2025 monthly cohort needed 12 months to hit $549. In essence, 4 orders now is the same as 12 orders 12 months back. We're pulling in cash about 3 times quicker per customer compared to merely 1 year ago, when we initially rolled things out. If you extend that path forward, today's cohorts are on a trajectory implying a 12-month LTR of $900-$1,100, as opposed to the $571 we achieved with mature cohorts. Within our mature cohorts, 81% of the cumulative revenue from 12 orders is driven by repeat buys. That positions our net repeat revenue far ahead of any publicly traded DTC peer that reveals a similar figure. Bell Ring stands at 52%, FIGS at 50%, Alidi at 45%. When it comes to retention, we're competing on an entirely different level. Considering the path we're on and the momentum we're witnessing, we're lifting our full year 2026 IM8 revenue guidance to $190 million-$210 million, an increase from the earlier range of $180 million-$200 million; for Q2, our expectation is total revenue between $46 million-$48 million, with IM8 delivering $44 million-$46 million, representing roughly 33% sequential quarterly growth in IM8 revenue alone. Crucially, this guidance leaves out the 3 Q4 product launches: hydration, creatine, and kids gummies. All of that is pure upside. I'd also like to take a few minutes to discuss what's really powering these figures. 3 elements drive this engine. Every one is a competitive advantage that builds on itself. The first is athlete equity alignment. David Beckham, as everyone is aware, is a co-founder of IM8. Aryna Sabalenka, the number 1 tennis player in the world, came aboard last June and is a partner as well. Our lineup has only grown stronger in Q1. We added Formula One driver Ollie Bearman a few weeks back. Then, more recently, 2-time NBA MVP Giannis. Actually, I was with Giannis in Milwaukee just last week. We captured some excellent content that we'll be able to share very soon. And most recently, we announced a partnership with Inter Miami CF as their official health supplements partner, which also carries an equity stake in Prenetics, nil rights with a minimum of 4 players, including Lionel Messi, and an IM8 nutrition center at their training facility. Each of these partners has equity in Prenetics. Their incentives build alongside ours across years, not just campaigns. Let me tackle something head-on, since I'm aware it's on people's minds. There's a belief that deals such as these run a huge cost; the truth is, they don't. Thanks to how strong our brand is and our equity alignment approach, we obtain extremely advantageous terms. When you compare it to the size of our revenue base, none of these partnerships cost us much money. They're far from the multimillion-dollar-per-year range that people might imagine. No challenger brand could put together the roster we're assembling, and we're doing it the right way. Honestly, every one of our individual partners uses the product daily. They spread the word to friends and family, and it catches on extremely quickly. Our science, we think, is the second moat we have. On our scientific advisory board sit people, doctors, physicians, and scientists from Mayo Clinic, Cedars-Sinai, and NASA as well. Behind our flagship product, we've finished a randomized controlled trial. We have 2 more randomized controlled trials in progress, one on gut health and one on longevity. By the end of the year, we think we can finish those 2 trials. In supplements, RCTs and strong clinical evidence are very uncommon; we think the investment pays off; it will give us a highly defensible moat. The third thing is our AI-driven marketing engine. For context, when we launched last year, we were running around 50 ads.
At this moment, at any point in time, roughly 3,000 Meta ads are live for us, representing a 60x jump from when we launched. Each week, we release around 600 fresh ads. Our AI builds a pipeline, runs tests, iterates, and picks things up more quickly than older DTC rivals do. One Aryna Sabalenka Instagram reel from last year generated 233 million views and ranked as the top social ad on Instagram for 2025. We're also branching out beyond our reliance on Meta right now. Across 2026, the mix of channels should shift from about 85% Meta to approximately 55%, running that same proven engine on TikTok, YouTube, and AppLovin to bring in fresh audiences with better tech. Let me take a few minutes now to discuss what lies ahead with our product roadmap, since that's truly at the heart of our growth narrative. During Q4 2026, we'll roll out 3 new products. We haven't brought this up before, but we're doing so today; these 3 new items fall into hydration, creatine, and kids' gummies; they aren't arbitrary line extensions. Every single one aims at a big, rapidly expanding category. Every single one leverages a structural edge we already possess, and every single one offers our current community additional reasons to incorporate IM8 into their everyday routines. Beginning with hydration, the worldwide hydration market sits at about $37 billion, expanding 8% annually, with leaders such as Gatorade, Liquid I.V., DripDrop, and Optimum Nutrition dominating it. Here's where the chance lies. A large portion of this space consists of commoditized sugar and electrolytes. IM8 hydration is crafted to the identical premium, science-backed, clean formulation benchmark as Daily Ultimate Essentials, third-party tested, NSF certified for sport. Hydration is a space where genuine athlete credibility decides everything. We've got Beckham, Sabalenka, Bearman, Giannis, and now Inter Miami. Whether on court or away from it, no challenger brand can rival that kind of alignment. Turning to creatine, the worldwide creatine market is around $1.3 billion and expanding 26% annually, the quickest-growing among the three. Creatine is enjoying a real cultural moment, spreading far past bodybuilding into cognition, healthy aging, and women's health. Rivals in this space include Optimum Nutrition, Muscle Milk, Thorne, and Create Wellness. Our point of difference is positioning. IM8 creatine combines strength with cognition, creatine plus focus. The majority of creatine available is a commodity powder. Ours will be developed for physical and mental performance alike, with the same scientific rigor underlying everything we produce. Third, kids' gummies. The worldwide kids supplement market is about $3.6 billion, expanding 8% annually, and honestly, it's the space most ready for disruption. The established players, Flintstones, Centrum Kids, L'il Critters, are all legacy brands, frequently packed with sugar and artificial ingredients, with minimal earned parental trust. The modern challenger space is still young. Our edge is straightforward. Parents who trust IM8 for themselves will trust it for their kids. Our current customers are mostly parents. A clean, science-backed, all-in-one, zero-sugar kids product is the most organic household expansion we could pursue. Here's the essential point that connects it all. Each of these product introductions is aimed at our existing community of more than 80,000 to 82,000 subscribers who are deeply engaged and extremely loyal; these aren't isolated wagers. They make every customer we currently serve more valuable; according to our internal modeling, using illustrative attach rates applied to that existing base, these 3 SKUs contribute roughly $178-$378 in additional second-year revenue for each customer. For context, that's a substantial lift sitting on top of the cohort economics I described earlier. They carry the brand into the home, they compound the lifetime value of the base, and none of this revenue is in our guidance. It is all upside. Let me turn to the capital allocation balance sheet. As of today, on the balance sheet, we hold approximately $147 million in cash and financial assets. During the past week, we sold our entire Bitcoin position, 510 Bitcoin, generating $41.3 million in cash proceeds already received. The board has also adopted a policy that the company will not purchase Bitcoin or any other digital assets going forward. Our capital is most productively deployed behind IM8. We will put these proceeds to work in 4 places: potential expansion of our authorized share repurchase program, accelerated IM8 DTC marketing where unit economics are proven, Q4 product pipeline, and continued international expansion. On the share buyback, we have repurchased approximately $19 million of the $40 million authorized amount since March 6. I, along with senior management, personally added another $2.75 million of open market purchases in previous trading windows; that is my conviction in this company rooted in my own capital. What's ahead? Let me close with where we're headed. We are operating in a $209 billion global supplements market, growing roughly 8% per year. Even at our current revenue targets for 2026, we represent approximately 0.1% market share with approximately $200 million revenue guidance for 2026. A $1 billion brand at just 0.5% global market share is well within reach. That's before laying in new products, new geographies, and additional subscription frequencies. The runway and upside is enormous, and we believe we are still in the very early innings. I'll say this plainly, I believe we are building a multi-billion dollar consumer health brand, a generational health brand. The product works, evidenced by the 16,000 five-star reviews you see. The science is real, the athletes are aligned, the engine compounds, and the data is doing the talking. With that, I'd like to welcome Brian Rosen, who joins us today as our Chief Financial Officer of IM8. In fact, it's Brian's first day today. Brian brings with us nearly 2 decades of finance leadership across premium consumer health and DTC subscription brands, and I believe he'll be a big asset moving forward. Brian, over to you.
Appreciate that, Danny. Morning to all of you. Happy to be on this call, and it happens to be day one for me. Before Stephen takes everyone through the Q1 figures piece by piece, I'll use just a couple of minutes to say who I am and what brought me here. A bit of background first. Close to 20 years of my career have been spent where consumer health, subscription supplements, and D2C e-commerce meet, with a focus on premium brands. My most recent post was Chief Financial Officer and Senior Vice President of E-commerce Operations at Wellbeam Consumer Health, a wellness platform backed by private equity. Inside Wellbeam's portfolio sat BioTrust in healthy aging nutrition, Eu Natural in women's hormonal and specialty supplements, plus TruSkin, a clean, plant-powered skincare brand. I came aboard TruSkin as CFO in 2020 and helped steer it through its acquisition by Wellbeam in 2021. Before that, I served as CFO at Penetrex, NATURELO Premium Supplements, and Ramp Inc. Each of those was successfully acquired. I've occupied the operator seat through scale, through capital raises, and through exits, and I understand what separates the brands that break through from the ones that stall. The reason I joined IM8 is pretty simple. Across every transaction I've ever worked on, the breakout brands share three traits. They all have a founder who cares deeply about the product, real science behind the formulations, and a team that treats every order and every dollar with discipline. From my first conversation with Danny, it was obvious this is the exact foundation IM8 is built on. David Beckham as a co-founding partner, world-class athletes as authentic, equity-aligned users, scientific advisory board members spanning Mayo Clinic, Cedars-Sinai, NASA, RCT grade clinical validation, and an AI and operating model that moves at a pace I'd never seen at this scale. Full disclosure, I've been an IM8 customer for over a year now. I was on The Beckham Stack way before I had met Danny or any of the team. I actually know that the product works because I use it. It was pretty fun to actually meet Danny for the first time, just having used the product for so long. The thing that really ultimately convinced me to join is the cohort data. It's just the math here is tremendous. In my career, I've looked at hundreds of cohort curves on supplement brands, but I've never seen LTV numbers like this. 81% repeat revenue, $240 new customer AOV, 2026 cohorts that are tracking to $900-$1,100 in 12-month revenue per customer. This isn't a marketing story. It's what disciplined unit economics looks like when a brand hits product-market fit at scale. My role here is gonna be quite clear. Build the financial foundation to support the next phase of growth. That means three things. First, scaling the finance organization globally to keep pace with the brand. The business is growing faster than most public companies in the category, and the financial infrastructure has to be ready. Next, we’re getting more precise about where capital goes and how unit economics are managed. Each marketing dollar has to be evaluated for payback and LTV, looking at every channel and every cohort. In a fast-growing D2C company, the CFO’s role is to ensure growth happens profitably, rather than merely getting bigger. Third, I’ll be collaborating closely with Danny Yeung and everyone else on the team so that our finance and operations base can support the path ahead. I’m eager to meet our shareholders and the analysts in the upcoming quarters. With that, I’ll hand things over to Stephen.
Okay, thanks Brian. Morning, everybody. Just a brief comment about the release we put out today before I jump into the figures. Our preliminary results are being published while we finish up quarter end closing procedures tied to certain non-cash variable items — more specifically, loan liabilities stemming from our December 2025 exchange program, plus the share consideration received from the Europa Sports Partners divestiture that closed in the first quarter. These are non-cash and non-operating in nature, so revenue, gross profit, operating loss, and adjusted EBITDA were not affected by them. Once those procedures wrap up, we expect to deliver full financial statements. Now to the financial results; on a continuing operating basis, Q1 2026 total revenue came in at $36 million, roughly 334% higher year-over-year versus $8.3 million in Q1 2025. IM8 accounted for $33.8 million. CircleDNA accounted for $2.2 million. Gross profit reached $23.3 million, an increase of about 315% year-over-year. Consolidated gross margin stood at 64.8%. At the IM8 segment level, gross margin was 64.3%, rising from 16.3% in Q4 2025 and 59.6% a year ago. That works out to a 400 basis point sequential improvement. Five factors compounded together drove this margin expansion: scale-driven manufacturing efficiencies as production volumes grew across our flagship lines. We negotiated unit economics with key contract manufacturers and ingredient suppliers. Favorable product mix and shift towards high-margin SKUs and subscriptions others. Packaging optimization and often improved fulfillment and freight efficiencies as order density grew across our 43 international markets. As volume scales further and supply chain initiatives mature, we expect to sustain these efficiencies through balance of 2026. Loss from operations this quarter was $8.9 million, versus $6 million in Q1 2025. Adjusted EBITDA loss came to $5.6 million, compared to $4.5 million in Q1 2025. This modest year-over-year increase reflects deliberate marketing investment behind the international quarterly subscription rollout, investment that, as Danny just walked through, is already showing in our cohort economics. I will also cite that the EBITDA range that we disclosed in the press release, which is not small, that range is driven entirely by the non-cash and non-operating value movements on borrowing liabilities and consideration shares as part of the Europa Sports Partners divestment. Again, these have no impact on operating performance. Turning to the balance sheet. Cash and cash equivalents at quarter end total $56 million. We carry no debt. We also held $34.8 million in Bitcoin and approximately $15 million in current financial assets measured at fair value through P&L, which actually represents our investment in investment funds. After our quarter end, we sold our entire 510 Bitcoin position for $41.3 million in cash proceeds, which we have already received in full. With this divestment completed, our estimated cash balance has grown to approximately $91.3 million, and combined with our financial investment in funds and at-scale cash, we have financial resources of about $147 million. Under the under $40 million cash repurchase program, we have actually deployed approximately $19 million, we bought approximately 968,000 shares. Our leadership group has been putting their own money in—buying an extra $2.75 million worth of shares on the open market during our earlier trading windows. Now, when we look forward, taking into account how Q1 turned out and April's IM8 monthly revenue hitting $14 million, that figure is actually 18.6% higher than the month before. So we're lifting our full year 2026 IM8 revenue outlook to $119 million-$210 million, which is above the $180 million-$200 million range we had before. Turning to Q2 in particular, we're expecting total revenue between $36 million-$48 million, and IM8 should account for $34 million-$46 million of that—roughly 33% growth on a sequential quarterly basis compared with IM8's Q1 revenue of $33.8 million. Like Danny mentioned, later this year in Q4 we intend to roll out three products: hydration, creatine, and kids gummies. Those aren't baked into the guidance we just gave and would be additional upside. So with that, let's take questions. Operator, please.
Hi, everyone. I appreciate you answering my question. This is Ryan Meyers — wonderful to meet you, and welcome aboard, so to speak. I'm eager to learn more about you all. To begin, I'm wondering how customer acquisition efficiency has been trending for you, particularly since your slide deck mentioned an effort to broaden the mix of marketing channels you use. And maybe you could explain how that would also improve efficiency?
Yes. Hi, Ryan. Great to hear from you. Regarding how we acquire customers — like I said before, about 85% of what we currently spend goes to Meta, while 15% goes to Google, correct? That split has stayed pretty steady, yes, from our launch through today; we think there's a larger global audience out there, which is why we've already begun expanding our customer acquisition channels to TikTok, yes, AppLovin, and YouTube, correct? At this point, we've already run spending experiments, I'd say, you know, of $3,000-$5,000 per day on those additional platforms. Naturally, when you're putting out a few thousand dollars, it's truly — as I said before — a matter of testing, learning, and iterating prior to scaling them up. Yes, we're confident that, you know, by the end of the year, we'll manage to successfully unlock fresh growth along with new channels and new audiences, and that will support our customer acquisition.
Understood, that's useful. For my final point, looking at those KPIs you provided, total customer orders declined roughly 4% from one quarter to the next, I believe. I think you mentioned that a shift in product mix was behind this. Is there anything we should take away regarding customer orders, and have you observed a recovery in Q2?
Actually, that drop in customer orders came about intentionally, yes. Like I said, during Q1, we made a conscious decision to move many of those customer orders to a quarterly basis. The real metric to focus on is the actual servings when viewed quarterly. Servings for each quarter did go up, yes. Since customers purchase 3 months worth at once, when you consider things on a quarterly and monthly level, your customer orders are going to fall. Meanwhile, the true count of servings will rise, correct? Our servings did rise, you know, by over, you know, 20% from the prior quarter. I believe that's an important metric to watch going forward, since it isn't a true apples to apples comparison, given that during the previous quarter we lacked, you know, the quarterly subscriptions included within the orders.
No, that's clear to me. I appreciate you letting me ask.
Sure.
Hello, George.
Hi, all. Hi, Danny. I appreciate you answering these. Several things I'd like to ask. To start, what took place during April and May? That was a significant surge. I'm simply wondering whether you might explain what caused it.
Well, we never stop refining and experimenting, correct? Once more, during Q1, a major focus was figuring out ways to boost our speed when it comes to creative variety across Meta and to raise both the quantity and standard of advertisements. As I said before, at this point we have around 3,000 ads running on Meta. Each week, we're launching somewhere between 600 and 800 fresh ads; over these last several months, we've truly generated a great deal of creative material. Again, you can't simply snap your fingers and demand that it go up. Even with Meta, plenty of daily testing is required before we can raise spending. Wanting more spend isn't enough—that's impossible without a creative variety engine in place, correct? And honestly, I'd say the reveal involving Giannis, plus Ollie Bearman and, more lately, Inter Miami CF—each of these creates a halo effect around the brand, its reputation, and its credibility, and that connects to the stronger momentum we've witnessed across April and May, all while we keep the cap levels we'd set before. Beyond that, we've noticed better retention among our January cohorts when it comes to renewal rates, correct. Since in January, those were the only cohorts eligible to renew come April, that factored in as well, and we've likewise observed that quarterly subscribers retain at a rate 10% above monthly subscribers when considering that initial four-month span.
All right. All right. Got it. For my second question, I suppose it builds on something Ryan asked. Could you get into specifics about TikTok? What stage of development are things at there? Have you actually accomplished a lot via TikTok? Perhaps you could discuss what you're doing to develop an affiliate network, along with your intentions and the timeline for when TikTok spending could genuinely scale up.
Absolutely. Yes. Once again, TikTok ranks among our top priorities, you know, for the current quarter. As an illustration, at present we've got around 500 affiliates on TikTok; from a testing standpoint, you know, we're putting out $3,000-$5,000 every day. By the close of the month, we anticipate reaching 1,000 affiliates and expanding further after that. Our outlook on TikTok is quite positive. As a matter of fact, we recently held a call with, you know, senior management at TikTok. They too are eager to have us on the platform and present in a major way. Yes. My belief is that within, you know, I'd say 3 to 6 months, substantial advancement on TikTok will become visible, and considering everything we've managed to achieve on Meta, I'm 100% certain we can replicate that on TikTok, which today is a platform where, you know, a great many consumers do their shopping.
All right, that answers my question. This final one from me is probably several questions in one. I didn't notice anything about marketing spend — specifically IM8 marketing spend — in the press release. It could be in there, though. Would you share what we spent on marketing this quarter? Then, my second question concerns the adjusted EBITDA guidance for the year. I didn't spot that in there either. Has your earlier adjusted EBITDA guide changed at all?
Yes. Stephen, how much did we spend on marketing in total during Q1?
Yep. The marketing spend was $22 million.
Right. When it comes to marketing spend, the overall figure came to $22 million. What else did you want to ask? Regarding adjusted EBITDA, isn't that right? Correct.
Regarding the adjusted EBITDA outlook for this year, is there anything different compared to what was given before?
Our earlier projection put adjusted EBITDA at approximately $15 million to $20 million. Right? So, considering how quickly we're expanding — moving from $60 million in full-year revenue last year up to $190 million-$210 million for the entire year now — we've managed to hold the adjusted EBITDA loss at nearly the same level as the prior year. My view is that our growth is happening rapidly while using capital efficiently.
All right, so the guidance for adjusted EBITDA is staying the same, right?
That's right.
All right, many thanks. I appreciate that.
Thank you, and I appreciate you answering our questions — welcome aboard, Brian.
Yes, thank you, Alex.
Our first question here. Hey, everyone. Regarding the raised guidance, I believe you mentioned some conservatism that was built in. The new SKUs aren't in there at this point. Should we be considering anything else that might create upside past the top end of the guidance?
Yeah, I mean. The new channels, I think there's definitely going to be more upside from those, correct? Naturally, we lack any hard numbers for those, such as TikTok, YouTube, AppLovin, and so forth. Those are new channels. Honestly, I'd say there's still going to be meaningful upside even with Meta as we grow, correct? Once we're active on TikTok, AppLovin, and YouTube, those will actually have a direct effect on Meta too. Yeah. I should also note that the 3 new SKUs haven't been included in our guidance simply because, again, the launch is set for Q4. Making any revenue forecasts feels premature, but based on our history and what we've accomplished, even with the launch of our Daily Ultimate Longevity last October, you've seen we can bring new products to market successfully. With our marketing flywheel and playbook, we're confident we'll do well with the new products, since there's still plenty of opportunity in the market for the hydration category, creatine, and kids gummies. One thing that truly sets us apart from many competitors is being a genuinely global brand, shipping to 43 countries. There are further upsides, not this year, but for 2027 and 2028, in that we haven't discussed China at all yet, correct? Once we choose when to launch there, China will be a major opportunity for us. India hasn't been mentioned either, correct? Significant upside lies ahead there. Yeah, for 26, I do believe we're very comfortable with our projections right now.
Thanks. Just one more thing. In the prepared remarks, you mentioned the randomized controlled trials and how they might apply to gut health and longevity. Could you expand a bit on the trial design, what kind of data you're hoping to collect, and how you intend to use it, especially compared to a study you ran before?
Sure. This will be an extremely rigorous study involving 2 twins. We've actually laid out 1 slide covering our RCT in the investor deck. It involves 120 participants for gut health and 180 for longevity. We'll measure biomarkers before and after people take the product for 8 weeks and 12 weeks. This is going to be a very strong trial, and recruitment kicks off within the next 30 to 45 days. We're really thrilled about it. What makes us confident we'll get positive results is the huge volume of feedback we've received from customers, both on our own platform and, if you check Trustpilot, we currently hold a 4.6 rating from 1,300 reviews. Altogether, we have over 16,000 5-star reviews. As I think I said before, it's extremely uncommon for a supplement brand to run an RCT on a finished product. Many companies might test specific ingredients or use branded ingredients, but they never test a finished product. The fact that we're willing to put money into this shows, you know, how strongly we believe in the product.
Thanks, Danny. Since we're on the topic of biomarkers, here's our final question. I realize the Superpower collaboration hasn't been around that long. Is there any preliminary insight into engagement or support — for instance, is a test, supplement, retest structure starting to emerge?
Yes. We rolled out the Superpower partnership only within the U.S., since that's the market where Superpower has launched. The initial data looks encouraging. Retesting hasn't happened on their end. I think the uptake rate sits at roughly 10%-15% of people who buy the product together with a blood test. Our expectation is that, as time goes on, people will be able to measure what IM8 does for them using a baseline blood marker test and then, after 90 days of using the product, which is precisely what we're carrying out in the RCT trials.
Thanks a lot.
Okay, thank you all. Yeah, I realize there's been plenty of, yeah, discussion regarding, you know, our growth — whether it can be kept up, whether it can last? I believe Q1 demonstrated that it absolutely can be not merely maintained, but expanding; during Q2, momentum continues to build. That gives me really strong confidence, as we begin and, you know, move deeper into the months of 2026. We think we're creating a once in a lifetime generational health supplements brand that within the next 3 to 4 years might genuinely become 1 of the world's biggest supplement brands. Thanks to all of you for following our journey, and it's an exciting time here.
Appreciate it — that brings today's teleconference and webcast to a close. At this point you're welcome to hang up, and we hope the rest of your day is great. Thanks so much for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Prenetics Global Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Prenetics Global Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.